Synaptic Plasticity Therapeutics for Parkinson's Disease

Synaptic Plasticity Therapeutics for Parkinson's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Synaptic Plasticity Therapeutics for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Synaptic Plasticity Enhancement</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Parkinson's Disease, Parkinson-Plus Syndromes</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05651464</td>
<td>Amantadine extended-release</td>
</tr>
<tr>
<td class="label">NCT05532657</td>
<td>D-Serine (NBTX-001)</td>
</tr>
<tr>
<td class="label">NCT05463731</td>
<td>Glutamate modulators</td>
</tr>
<tr>
<td class="label">NCT05508789</td>
<td>Synaptic plasticity enhancer</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Amantadine ER</td>
<td>Adamas</td>
</tr>
<tr>
<td class="label">D-serine</td>
<td>多家</td>
</tr>
<tr>
<td class="label">CX516</td>
<td>Cortex</td>
</tr>
</table>

Synaptic Plasticity Therapeutics for Parkinson's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Synaptic Plasticity Therapeutics for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Synaptic Plasticity Enhancement</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Parkinson's Disease, Parkinson-Plus Syndromes</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT05651464</td>
<td>Amantadine extended-release</td>
</tr>
<tr>
<td class="label">NCT05532657</td>
<td>D-Serine (NBTX-001)</td>
</tr>
<tr>
<td class="label">NCT05463731</td>
<td>Glutamate modulators</td>
</tr>
<tr>
<td class="label">NCT05508789</td>
<td>Synaptic plasticity enhancer</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Amantadine ER</td>
<td>Adamas</td>
</tr>
<tr>
<td class="label">D-serine</td>
<td>多家</td>
</tr>
<tr>
<td class="label">CX516</td>
<td>Cortex</td>
</tr>
</table>

Synaptic plasticity dysfunction is a central pathological feature of Parkinson's disease (PD), contributing to both motor and non-motor symptoms. This page explores therapeutic technologies targeting synaptic plasticity enhancement, including mechanisms of action, clinical trials, and the developing pipeline of disease-modifying treatments.

Overview

Synaptic loss and dysfunction in Parkinson's disease occurs early in disease progression and correlates strongly with clinical disability. Unlike dopaminergic therapies that provide symptomatic relief, synaptic plasticity-targeted approaches aim to preserve or restore synaptic function, potentially slowing or halting disease progression. [@calabresi2020]

Pathophysiology of Synaptic Dysfunction in PD

Dopaminergic denervation-induced changes

The progressive loss of [dopaminergic neurons](/diseases/parkinsons-disease) in the [substantia nigra pars compacta](/brain-regions/substantia-nigra) leads to:

• Striatal synaptic remodeling: Loss of dopaminergic modulation of medium spiny neurons
• Cortical-striatal circuit dysfunction: Disrupted cortico-striatal connectivity
• Thalamic over-activation: Abnormal excitatory drive to motor cortex
• Network-level desynchronization: Disrupted beta-band oscillations

Synaptic plasticity impairments

Key mechanisms include:

• Long-term potentiation (LTP) deficits: Impaired NMDA receptor-dependent synaptic strengthening
• Long-term depression (LTD) dysregulation: Abnormal synaptic weakening
• Dendritic spine loss: Reduced spine density in corticostriatal neurons
• Extrasynaptic receptor changes: Altered tonically active NMDA/AMPA receptors

Mechanisms of Therapeutic Intervention

1. NMDA Receptor Modulation

[NMDA receptors](/entities/nmda-receptor) are critical for synaptic plasticity induction. In PD, NMDA receptor function is altered, contributing to plasticity deficits. [@paoletti2011]

Approaches

NMDA Receptor Partial Agonists

• Target: GluN2A/2B-containing NMDA receptors
• Mechanism: Sub-maximal activation to enhance plasticity without excitotoxicity
• Example: D-serine supplementation (co-agonist)

• Target: Allosteric sites on NMDA receptors
• Mechanism: Enhance receptor trafficking and function
• Challenge: Balancing efficacy with side effects

• Target: GluN2B subunit-containing receptors
• Mechanism: Enhance synaptic plasticity in striatal neurons
• Status: Preclinical validation ongoing

2. AMPA Receptor Modulation

[AMPA receptors](/proteins/ampa-receptor) mediate fast excitatory neurotransmission and are crucial for synaptic plasticity expression. [@chen2019]

Approaches

Positive Allosteric Modulators (PAMs)

• Target: Allosteric sites on AMPA receptors
• Mechanism: Enhance receptor function and promote LTP
• Example: CX516 (Ampakine)

• Target: AMPA receptor agonists with favorable properties
• Mechanism: Direct activation to enhance synaptic transmission
• Challenge: Rapid desensitization

• Target: Proteins regulating receptor internalization/externalization
• Mechanism: Promote surface expression
• Example: Targeting PICK1, GRIP1

3. Dendritic Spine Remodeling

Dendritic spines are the primary sites of excitatory synapses. In PD, spine density decreases, contributing to synaptic dysfunction. [@nakao2019]

Approaches

Small Molecule Enhancers

• Target: Proteins regulating spine formation and maintenance
• Mechanisms:
• Actin cytoskeleton modulators
• Rho GTPase pathway modifiers
• Synaptic scaffolding protein stabilizers

• Target: BDNF/TrkB pathway
• Mechanism: Enhance neurotrophic support for spine maintenance
• Challenge: Blood-brain barrier penetration

• Target: Synaptic cell adhesion molecules (neuroligin, neurexin)
• Mechanism: Enhance synaptic formation and stability

4. LTP/LTD Balance Restoration

Synaptic plasticity involves a balance between strengthening (LTP) and weakening (LTD) processes. In PD, this balance is disrupted.

Approaches

Phosphatase Inhibitors

• Target: Protein phosphatases (calcineurin, PP1)
• Mechanism: Shift balance toward LTP
• Status: Preclinical research

• Target: CaMKII, PKA, PKC pathways
• Mechanism: Enhance LTP induction mechanisms
• Example: Bryostatin (PKC activator)

• Target: cAMP/PKA signaling pathway
• Mechanism: Enhance second messenger signaling
• Example: Phosphodiesterase inhibitors

Clinical Trials in Synaptic Plasticity for PD

Active and Recruiting Trials

Completed Trials

CX516 (Ampakine) Studies

• Phase II for PD cognition
• Results: Modest improvement in cognitive measures
• Challenge: Short half-life limiting efficacy

• NMDA receptor partial agonist
• Mixed results in PD studies
• Ongoing optimization of dosing

• NMDA receptor antagonist with plasticity effects
• Shown to improve dyskinesias
• Mechanism may involve plasticity normalization

Therapeutic Candidates and Pipeline

Clinical Stage

Preclinical Candidates

Novel NMDA Modulators

• GluN2B-selective compounds
• Allosteric modulators with improved side effect profiles

• Optimized Ampakine derivatives
• Positive allosteric modulators with better brain penetration

• Actin polymerization modulators
• Rho kinase inhibitors

• Combined dopamine and plasticity enhancement
• Disease-modifying small molecules

Combination Approaches

With Dopaminergic Therapies

With Non-Dopaminergic Approaches

Challenges and Considerations

Blood-Brain Barrier Penetration

Many plasticity-targeting compounds face challenges reaching the brain:

• Molecular weight and polarity requirements
• Active transport mechanisms
• Efflux transporter considerations

Selectivity Issues

Targeting synaptic plasticity without disrupting normal function:

• Dose-dependent effects on neural circuits
• Region-specific targeting (striatum vs. cortex)
• Temporal specificity (acute vs. chronic treatment)

Biomarker Development

Measuring synaptic plasticity in clinical trials:

• PET ligands for synaptic density (SV2A)
• CSF synaptic biomarkers (neurogranin, SNAP-25)
• Electrophysiological measures (TMS)
• Behavioral readouts

Translation from Preclinical Models

Challenges in translating findings:

-rodent to human differences

• Age-related plasticity changes
• Chronic vs. acute disease modeling

Emerging Research Directions

Gene Therapy Approaches

• Delivery of plasticity-enhancing genes
• Viral vectors targeting specific neuronal populations
• CRISPR-based modifications

Cell-Based Therapies

• Stem cell-derived neurons with enhanced plasticity
• Gene-modified cells secreting neurotrophic factors
• Organoid-based approaches

Neuromodulation Synergy

Combining with:

• Deep brain stimulation
• Transcranial magnetic stimulation
• Transcranial direct current stimulation

Related Mechanisms and Pages

• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms)
• [Long-Term Potentiation](/mechanisms/long-term-potentiation)
• [NMDA Receptor Signaling](/entities/nmda-receptor)
• [AMPA Receptor Function](/proteins/ampa-receptor)
• [Dendritic Spines](/cell-types/dendritic-spines)
• [Synaptic Loss in Neurodegeneration](/cell-types/synaptic-loss-neurons)
• [Striatal Medium Spiny Neurons](/cell-types/striatal-medium-spiny-neurons)
• [Parkinson's Disease Treatment](/therapeutics/parkinson-treatment)
• [Dopamine Agonists](/therapeutics/dopamine-agonists)
• [Exenatide-Parkinson's Trial](/clinical-trials/exenatide-parkinsons)

Related Therapeutic Approaches

• [Synaptic Stabilizers](/therapeutics/synaptic-stabilizers)
• [Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy)
• [Neuroprotection Strategies](/therapeutics/neuroprotection)
• [Neuroplasticity Enhancement](/mechanisms/neuroplasticity)
• [Physical Exercise for Parkinson's](/therapeutics/physical-exercise-parkinsons)

See Also

• [Parkinson's Disease Overview](/diseases/parkinsons-disease)
• [Parkinson's Disease Treatment](/therapeutics/parkinson-treatment)
• [Synaptic Loss MSA Trial](/clinical-trials/synaptic-loss-msa-nct05121012)
• [Drug Pipeline for PD](/clinical-trials/drug-pipeline)
• [Movement Disorder Clinical Trials](/clinical-trials/movement-disorder-trials)

External Links

• [Parkinson's Foundation](https://www.parkinson.org/)
• [Michael J. Fox Foundation](https://www.michaeljfox.org/)
• [ClinicalTrials.gov Parkinson's Disease](https://clinicaltrials.gov/ct2/results?cond=Parkinson+Disease)
• [PubMed Synaptic Plasticity PD](https://pubmed.ncbi.nlm.nih.gov/?term=synaptic+plasticity+Parkinson)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Epigenetic Memory Reprogramming for Alzheimer&#x27;s Disease](/hypothesis/h-29ef94d5) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BDNF, CREB1, synaptic plasticity genes
• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [SASP-Mediated Cholinergic Synapse Disruption](/hypothesis/h-1acdd55e) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: MMP2/MMP9
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7
• [Complement C1QA Spatial Gradient in Cortical Layers](/hypothesis/h-seaad-5b3cb8ea) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: C1QA
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF

Related Analyses:

• [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Mechanistic role of APOE in neurodegeneration](/analysis/SDA-2026-04-01-gap-auto-fd6b1635d9) &#x1f504;
• [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Synaptic Plasticity Therapeutics for Parkinson's Disease discovered through SciDEX knowledge graph analysis: